Health

Obesity Drugmaker Kailera Soars 63% After $625 Million IPO

The New York Stock Exchange.
Photographer: Michael Nagle/Bloomberg

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

By Avalon Pernell

April 17, 2026 at 5:41 PM UTC

Updated on

April 17, 2026 at 8:13 PM UTC

Kailera Therapeutics Inc. shares surged 63% after the clinical-stage biotechnology company focused on obesity raised $625 million in an upsized US initial public offering.

The company’s shares closed at $26 each on Friday, above its IPO price of $16 apiece. The Waltham, Massachusetts-based firm had marketed 33.3 million shares for $14 to $16 each.